company background image
9995

RemeGen SEHK:9995 Stock Report

Last Price

HK$44.45

Market Cap

HK$28.3b

7D

30.5%

1Y

-64.1%

Updated

25 Jun, 2022

Data

Company Financials +
9995 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends0/6

9995 Stock Overview

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.

RemeGen Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for RemeGen
Historical stock prices
Current Share PriceHK$44.45
52 Week HighHK$145.50
52 Week LowHK$25.05
Beta0
1 Month Change65.24%
3 Month Change-15.58%
1 Year Change-64.12%
3 Year Changen/a
5 Year Changen/a
Change since IPO-36.32%

Recent News & Updates

May 04
RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

Even though RemeGen Co., Ltd. ( HKG:9995 ) posted strong earnings recently, the stock hasn't reacted in a large way. We...

Shareholder Returns

9995HK BiotechsHK Market
7D30.5%13.0%2.1%
1Y-64.1%-53.7%-23.3%

Return vs Industry: 9995 underperformed the Hong Kong Biotechs industry which returned -53.7% over the past year.

Return vs Market: 9995 underperformed the Hong Kong Market which returned -23.3% over the past year.

Price Volatility

Is 9995's price volatile compared to industry and market?
9995 volatility
9995 Average Weekly Movement13.9%
Biotechs Industry Average Movement10.2%
Market Average Movement7.0%
10% most volatile stocks in HK Market13.8%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 9995 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: 9995's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
20082,121Jianmin Fanghttps://www.remegen.com

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors.

RemeGen Fundamentals Summary

How do RemeGen's earnings and revenue compare to its market cap?
9995 fundamental statistics
Market CapCN¥24.09b
Earnings (TTM)CN¥173.91m
Revenue (TTM)CN¥1.57b

117.5x

P/E Ratio

13.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
9995 income statement (TTM)
RevenueCN¥1.57b
Cost of RevenueCN¥163.40m
Gross ProfitCN¥1.41b
Other ExpensesCN¥1.23b
EarningsCN¥173.91m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.32
Gross Margin89.59%
Net Profit Margin11.08%
Debt/Equity Ratio0%

How did 9995 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 9995 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9995?

Other financial metrics that can be useful for relative valuation.

9995 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.8x
Enterprise Value/EBITDA221x
PEG Ratio1.5x

Price to Earnings Ratio vs Peers

How does 9995's PE Ratio compare to its peers?

9995 PE Ratio vs Peers
The above table shows the PE ratio for 9995 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average20.5x

Price-To-Earnings vs Peers: 9995 is expensive based on its Price-To-Earnings Ratio (117.5x) compared to the peer average (20.5x).


Price to Earnings Ratio vs Industry

How does 9995's PE Ratio compare vs other companies in the Biotechs Industry?

Price-To-Earnings vs Industry: 9995 is expensive based on its Price-To-Earnings Ratio (117.5x) compared to the Hong Kong Biotechs industry average (14.7x)


Price to Earnings Ratio vs Fair Ratio

What is 9995's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9995 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio117.5x
Fair PE Ratio43.7x

Price-To-Earnings vs Fair Ratio: 9995 is expensive based on its Price-To-Earnings Ratio (117.5x) compared to the estimated Fair Price-To-Earnings Ratio (43.7x).


Share Price vs Fair Value

What is the Fair Price of 9995 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9995 (HK$44.45) is trading below our estimate of fair value (HK$141.36)

Significantly Below Fair Value: 9995 is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: 9995 is poor value based on its PEG Ratio (1.5x)


Discover undervalued companies

Future Growth

How is RemeGen forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


80.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9995's forecast earnings growth (80.5% per year) is above the savings rate (1.5%).

Earnings vs Market: 9995's earnings (80.5% per year) are forecast to grow faster than the Hong Kong market (17% per year).

High Growth Earnings: 9995's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 9995's revenue (34.5% per year) is forecast to grow faster than the Hong Kong market (10.2% per year).

High Growth Revenue: 9995's revenue (34.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 9995 is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has RemeGen performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


22.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 9995 has a high level of non-cash earnings.

Growing Profit Margin: 9995 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 9995 has become profitable over the past 5 years, growing earnings by 22.4% per year.

Accelerating Growth: 9995 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 9995 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (12.8%).


Return on Equity

High ROE: 9995's Return on Equity (3.1%) is considered low.


Discover strong past performing companies

Financial Health

How is RemeGen's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 9995's short term assets (CN¥4.4B) exceed its short term liabilities (CN¥586.7M).

Long Term Liabilities: 9995's short term assets (CN¥4.4B) exceed its long term liabilities (CN¥90.2M).


Debt to Equity History and Analysis

Debt Level: 9995 is debt free.

Reducing Debt: 9995 had no debt 5 years ago.

Debt Coverage: 9995 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 9995 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is RemeGen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 9995's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 9995's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 9995's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 9995's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 9995 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Jianmin Fang (58 yo)

13.67yrs

Tenure

Dr. Jianmin Fang is Co-Founder at RemeGen Co., Ltd. She has been Director, Chief Executive Officer and Chief Scientific Officer of RemeGen Co., Ltd. since October 16, 2008, and redesignated as an Executive...


Leadership Team

Experienced Management: 9995's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: 9995's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.


Top Shareholders

Company Information

RemeGen Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: RemeGen Co., Ltd.
  • Ticker: 9995
  • Exchange: SEHK
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$28.266b
  • Shares outstanding: 539.20m
  • Website: https://www.remegen.com

Number of Employees


Location

  • RemeGen Co., Ltd.
  • 58 Middle Beijing Road
  • Yantai Development Zone
  • Yantai
  • Shandong Province
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/25 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.